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pioglitazone Modulates the 
Vascular contractility in 
Hypertension by interference with 
ET-1 Pathway
Roberto palacios-Ramírez  1,2,4,5, Raquel Hernanz1,2,5, Angela Martín  1,2, José V. Pérez-
Girón1,6, María T. Barrús  1,2, Zoe González-carnicero1, Andrea Aguado3, Frederic Jaisser4, 
Ana M. Briones2,3, Mercedes Salaices2,3 & María J. Alonso1,2*
Endothelin-1 (ET-1) is an important modulator of the vascular tone and a proinflammatory molecule 
that contributes to the vascular damage observed in hypertension. Peroxisome-proliferator activated 
receptors-γ (PPARγ) agonists show cardioprotective properties by decreasing inflammatory 
molecules such as COX-2 and reactive oxygen species (ROS), among others. We investigated the 
possible modulatory effect of PPARγ activation on the vascular effects of ET-1 in hypertension. In 
spontaneously hypertensive rats (SHR), but not in normotensive rats, ET-1 enhanced phenylephrine-
induced contraction through etA by a mechanism dependent on activation of TP receptors by COX-2-
derived prostacyclin and reduction in NO bioavailability due to enhanced ROS production. In SHR, the 
PPARγ agonist pioglitazone (2.5 mg/Kg·day, 28 days) reduced the increased ETA levels and increased 
those of etB. After pioglitazone treatment of SHR, ET-1 through ETB decreased ROS levels that 
resulted in increased NO bioavailability and diminished phenylephrine contraction. In vascular smooth 
muscle cells from SHR, ET-1 increased ROS production through AP-1 and NFκB activation, leading to 
enhanced COX-2 expression. These effects were blocked by pioglitazone. In summary, in hypertension, 
pioglitazone shifts the vascular ETA/ETB ratio, reduces ROS/COX-2 activation and increases NO 
availability; these changes explain the effect of ET-1 decreasing phenylephrine-induced contraction.
Peroxisome-proliferator activated receptors (PPARs) are ligand-activated transcription factors that belong to the 
nuclear hormone receptor superfamily and regulate the expression of genes involved in glucose and lipids metab-
olism1. PPARγ is expressed in all vascular cells, including vascular smooth muscle cells (VSMC)2. PPARγ activa-
tion reduces reactive oxygen species (ROS) production and inflammatory molecules such as cyclooxygenase-2 
(COX-2) by interfering with mitogen-activated protein kinases (MAPK) and/or proinflammatory transcription 
factors3–6, explaining the cardioprotective effect of PPARγ agonists7. In this sense, PPARγ ligands antagonize the 
vascular damage and functional alterations observed in inflammatory pathologies such as hypertension8–10.
Endothelin-1 (ET-1), the most important isoform of the endothelin family, is mainly produced by endothe-
lial cells, although other vascular cells, including VSMC, release ET-1 in response to different stimuli11,12. ET-1 
interacts with two different G-protein-coupled receptors, ET-1 receptor A (ETA) and ET-1 receptor B (ETB). In 
the vasculature, ETA receptors are located in the smooth muscle cells and cause sustained vasoconstriction; ETB 
predominate in endothelial cells and mediate vasodilatation by release of endothelium-derived relaxing factors 
(nitric oxide -NO-, prostacyclin-PGI2- and/or endothelium-derived hyperpolarizing factor), although a small 
population of this subtype is present in VSMC causing vasoconstriction in certain vascular beds13. In addition to 
the mentioned vasoconstrictor effect, ET-1 stimulates the renin-angiotensin-aldosterone and sympathetic nerv-
ous systems and possesses cardiac positive inotropic and chronotropic effects; then, ET-1 has a pivotal role at 
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cardiovascular level14. It is well known that ET-1 contributes to the pathophysiological alterations observed in 
different inflammatory disorders, such as hypertension15–17. Thus, endogenous ET-1 seems to mediate some of 
the deleterious cardiovascular effects attributed to angiotensin II, such as the renal effects, the cardiac fibrosis or 
hypertrophy18–20. Besides its vasoconstrictor effect, subthreshold concentrations of ET-1 increase the contractility 
to other vasoactive agents21–23. Furthermore, ET-1 increases oxidative stress and proinflammatory enzymes such 
as COX-23,5,24–27 that are involved in the hypertension-associated vascular damage28–30.
PPARγ activation reduces ET-1 levels31,32; in this sense, we have described that, by downregulating ET-1 tran-
scription, pioglitazone inhibits angiotensin II-associated vascular COX-2 expression in hypertension5. However, 
the effect of PPARγ activation on the vascular actions of ET-1 is less known. We hypothesize that glitazones con-
tribute to reduce the hypertension-associated vascular damage by interfering with ET-1-induced vasoactive and 
proinflammatory effects. For this, in vessels or VSMC from hypertensive rats we have analysed: (1) the effect of 
a subthreshold concentration of ET-1 on phenylephrine responses as well as the role of NO and COX-2-derived 
prostanoids in such effect; (2) the mechanisms involved in the ET-1-induced COX-2 expression; (3) the interfer-
ence induced by the PPARγ agonist pioglitazone of these ET-1 effects.
Results
ET-1 enhances phenylephrine contraction in resistance arteries from hypertensive rats via 
etA. In a previous report, we found greater aortic ET-1 mRNA levels in spontaneously hypertensive rats (SHR) 
compared to Wistar Kyoto (WKY) rats5. Here, we also found greater ETA mRNA levels in both aortic (Fig. 1a) and 
mesenteric segments (Fig. 1b) from SHR than WKY, while those of ETB were similar in both strains (Fig. 1a,b). In 
order to analyse whether this different receptor expression pattern has functional consequences, reactivity exper-
iments were performed. ET-1, at a concentration (1 nM) which does not induce any vasoactive effect, enhanced 
the phenylephrine-induced contraction in mesenteric resistance arteries (MRA) from SHR (Emax: Control, 
113.6 ± 2.2%; ET-1, 122.8 ± 2.3%, P < 0.05; pD2: Control, 5.62 ± 0.02; ET-1, 5.82 ± 0.02; P < 0.05), without affect-
ing the contraction in WKY arteries (Fig. 1c). The effect of ET-1 on phenylephrine responses was diminished by 
endothelium removal in arteries from SHR, as shown by the lack of effect of ET-1 in Emax (Control, 117.6 ± 1.1%; 
ET-1, 119.6 ± 2.9%, P>0.05) and by the decreased dAUC values (Fig. 1c). The ETA antagonist BQ123 (1 µM) 
abolished the effect of ET-1 in intact SHR segments; however, no effect of BQ788 (1 µM), an ETB antagonist, was 
observed (Fig. 1d). On the other hand, ET-1 did not affect the vascular mRNA levels of PPARγ (Fig. 1e).
Reduced NO bioavailability, likely by increase of oxidative stress, contributes to the 
ET-1-induced enhancement of phenylephrine contraction in MRA from SHR. The incubation 
with the NOS inhibitor N-nitro-L-arginine methyl ester (L-NAME, 0.1 mM) leftward shifted the phenylephrine 
contraction in MRAs from SHR, being this effect reduced in ET-1-treated arteries (Fig. 2a), suggesting that ET-1 
reduces the negative modulation induced by NO on phenylephrine contraction; in agreement, and despite the 
increase of eNOS expression induced by ET-1 (Fig. 2b), the basal NO levels were lower in ET-1-incubated seg-
ments (Fig. 2c). It is well accepted that ET-1 increases oxidative stress at vascular level24,26,27. Accordingly, ET-1 
augmented the vascular NADPH oxidase (NOX) activity (Fig. 2d) and the NOX inhibitor ML-171 (0.5 µM) 
reduced the phenylephrine-induced contraction only in ET-1-treated arteries (Fig. 2e). These results suggest 
that oxidative stress, by reducing NO bioavailability, would contribute to enhance the phenylephrine-induced 
response after ET-1 treatment. In addition, ET-1 impaired the vasodilator response induced by ACh (Fig. 2f). 
After L-NAME incubation ACh-induced relaxation was reduced to a similar level in both ET-1 untreated and 
treated segments (Fig. 2f), suggesting that ET-1 impaired the NO contribution to endothelium-dependent vas-
odilator responses. In agreement, ACh-induced NO levels were lower after ET-1 incubation than in control seg-
ments (Fig. 2g).
COX-2 derivatives acting on TP receptors are involved in ET-1-induced potentiation of phenyle-
phrine contraction in MRA from SHR. We have previously described that ET-1 increases COX-2 expres-
sion in VSMCs from SHR5. Then, we analysed the contribution of COX-derived prostanoids to the effect of ET-1 
on phenylephrine responses in SHR arteries. Both the non-selective COX inhibitor indomethacin (10 µM) and 
the selective COX-2 inhibitor NS398 (1 µM), reduced phenylephrine contraction only in ET-1-treated segments 
(Fig. 3a), suggesting that COX-2-derived vasoconstrictor prostanoids contribute to the increase of phenylephrine 
response induced by ET-1 in hypertensive animals. The EP1–3 receptor antagonist SC19220 (10 µM) did not affect 
phenylephrine response neither in control nor in ET-1-incubated segments (data not shown); however, the TxA2 
receptor (TP) antagonist SQ29,548 (1 µM) reduced phenylephrine contraction only in ET-1-incubated MRA 
(Fig. 3a). Notably, the TxA2 synthase inhibitor furegrelate (1 µM) did not affect phenylephrine-induced con-
traction in either control or ET-1-treated segments (data not shown), apparently excluding TXA2 as the vaso-
constrictor prostanoid responsible for ET-1-induced hypercontractility. It is well known that PGI2 is the main 
COX-derived vasodilator prostanoid; however, in some conditions such as hypertension or aging, prostacyclin 
can induce vasoconstriction via TP receptors10,33. We found that the PGI2 synthase inhibitor tranylcypromine 
(10 µM) reduced the phenylephrine contraction only in ET-1-incubated segments (Fig. 3a). In agreement, ET-1 
increased PGIS gene expression in VSMC from SHR (relative expression 1.46 ± 0.13, n = 4; P < 0.05). Together, 
these results suggest that COX-2-derived PGI2, via TP receptors, contributes to the ET-1-induced enhancement 
of phenylephrine-response in MRAs from SHR.
In endothelium-denuded segments, NS398 and SQ29,548 still reduced the phenylephrine contraction in 
ET-1-incubated segments (Fig. 3b), suggesting that ET-1 increased the production of COX-2-derived vasocon-
strictor prostanoids from VSMC.
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Figure 1. Vascular ET-1 receptors expression and effect of ET-1 on phenylephrine contraction in MRA. ETA 
and ETB mRNA levels in aortic (a) and mesenteric (b) segments from WKY and SHR; *P < 0.05 by Student's 
t test. (c) Effect of ET-1 (1 nM, 90 min) on the concentration-response curve to phenylephrine (Phe) in 
endothelium-intact (E+) and denuded (E-) segments from WKY and SHR; *P < 0.05 by two-way ANOVA with 
repeated measures followed by Sidak post hoc test. Differences of the area under the concentration-response 
curve (dAUC) to Phe in E+ and E- segments from SHR are also shown; *P < 0.05 by Student's t test. (d) Effect 
of BQ123 (1 µM) and BQ788 (1 µM) on the response to Phe in E+ segments from SHR treated with ET-1; 
*P < 0.05 vs control; #P < 0.05 vs ET-1 by two-way ANOVA with repeated measures followed by Tukey post 
hoc test. (e) Effect of ET-1 on the vascular expression of PPARγ; statistical analysis by Student's t test. n denotes 
number of experiments.
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Oxidative stress contributes to ET-1-induced COX-2 expression in VSMC from SHR. Next, 
we analyzed the mechanisms involved in the induction of COX-2 by ET-1 in cultured VSMCs from SHR. As 
shown in Fig. 4a–c the antioxidant apocynin but not the H2O2 scavenger catalase (1,000 U/ml), reduced the 
ET-1-induced COX-2 expression, suggesting the contribution of superoxide anion to the ET-1-induced COX-2 
expression. In agreement, ET-1 (0.1 µM) increased NOX-1 protein and mRNA levels (Fig. 4d,e), NOX-4 mRNA 
levels (Fig. 4f), NADPH oxidase activity and superoxide anion production (Fig. 4g,h).
Figure 2. Role of nitric oxide and oxidative stress on ET-1-induced potentiation of phenylephrine response 
in MRA from hypertensive rats. (a) Effect of 0.1 mM L-NAME on the concentration-response curve to 
phenylephrine (Phe) in control and ET-1-incubated (1 nM, 90 min) segments from SHR; *P < 0.05 by two-way 
ANOVA with repeated measures followed by Sidak post hoc test. Differences of the AUC (dAUC) to Phe in the 
presence and the absence of L-NAME are also shown; *P < 0.05 by Student's t test. (b) Effect of ET-1 on eNOS 
mRNA levels in vascular segments; statistical analysis by Student's t test. (c) Quantification of nitric oxide (NO) 
release and (d) NADPH oxidase activity in control and ET-1-incubated segments from SHR; statistical analysis 
by Student’s t test. (e) Effect of 0.5 µM ML-171 on the concentration-response curve to Phe in control and ET-1-
incubated segments from SHR; *P < 0.05 by two-way ANOVA with repeated measures followed by Sidak post-
test. (f) Effect of ET-1 and L-NAME on the concentration-response curve to acetylcholine (ACh) in segments 
from SHR; *P < 0.05 vs Control; #P < 0.05 vs ET-1 by two-way ANOVA with repeated measures followed by 
Sidak post hoc test. (g) Quantification of ACh-induced NO release in control and ET-1-incubated segments 
from SHR; statistical analysis by Student's t test. n denotes number of experiments.
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It has been described that ET-1 activates several transcription factors3,34,35.We then analysed the contribu-
tion of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and activator protein 1 (AP-1) 
on the ROS/COX-2 pathway. In VSMCs from SHR, the proteasome inhibitor lactacystin (10 µM) reduced the 
Figure 3. Role of cyclooxygenase-derived prostanoids on ET-1-induced potentiation of phenylephrine response 
in MRA from hypertensive rats. (a) Effect of 10 µM indomethacin (Indo), 1 µM NS398, 1 µM SQ29,548 and 10 µM 
tranylcypromine (Tranyl) on the concentration-response curve to phenylephrine (Phe) in intact control and 
ET-1-incubated (1 nM, 90 min) segments from SHR. (b) Effect of NS398 and SQ29,548 on the concentration-
response curve to Phe in endothelium-denuded (E-) segments from SHR incubated with ET-1. *P < 0.05 by two-
way ANOVA with repeated measures followed by Sidak post-test. n denotes number of experiments.
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ET-1-induced NOX-1 mRNA levels and NADPH oxidase activity (Fig. 5a,b) and COX-2 expression (Fig. 5c,d). 
In addition, ET-1 increased the nuclear expression of the NFκB p65 subunit (Fig. 5e); the immunofluorescence 
experiments confirmed the augmented nuclear localization of p65 (Fig. 5f).
The specific JNK inhibitor SP600125 (20 µM) also diminished the ET-1-induced NOX-1 expression and 
NADPH oxidase activity (Fig. 6a,b) as well as COX-2 protein and mRNA levels (Fig. 6c,d). Furthermore, ET-1 
increased JNK1/2 phosphorylation and c-jun expression (Fig. 6e,f), supporting the activation of AP-1. Altogether, 
these results suggest that ET-1 induces COX-2 expression by increasing ROS production through NFκB and AP-1 
pathways.
After pioglitazone treatment of SHR, ET-1 increased NO bioavailability reducing phenyle-
phrine contraction in MRA through ETB receptors. It is well known that glitazones are cardioprotective 
compounds with antiinflammatory and antioxidant properties7. In previous reports, we showed that pioglitazone 
improved vascular function and reduced the increased vascular ET-1 expression in SHR5,10. Herein we found 
Figure 4. Contribution of oxidative stress to the ET-1-induced COX-2 expression in VSMC from hypertensive 
rats. (a) Effect of catalase (Cat, 1,000 U/ml) on ET-1 (0.1 µM, 1 h)-induced COX-2 mRNA levels. Effect of 
apocynin (Apo, 30 µM) on ET-1-induced COX-2 protein expression (b) and mRNA levels (c). Effect of ET-1 on 
NOX-1 protein expression (d) and mRNA levels (e), NOX-4 mRNA levels (f), NADPH oxidase activity (g) and 
superoxide anion (O2.−) production (h) in VSMC from SHR. Statistical analysis by Student's t-test; *P < 0.05 
vs control (Ctrl) and #P < 0.05 vs ET-1. n denotes number of experiments. Full-length blots are presented in 
Supplementary Figs S1 and S2.
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Figure 5. Contribution of NFκB to the ET-1-induced oxidative stress and COX-2 expression in VSMC from 
hypertensive rats. Effect of lactacystin (Lac, 10 µM) on NOX-1 mRNA levels (a), NADPH oxidase activity 
(b), COX-2 protein expression (c) and mRNA levels (d) induced by ET-1 (0.1 µM, 1 h). (e) Effect of ET-1 
(0.1 µM, 45 min) on nuclear p65 NFκB protein expression in VSMC from SHR; a representative blot of the 
cytosolic (Cy) and nuclear (Nu) expression is shown below; TATA-binding protein (TBP) and GAPDH (after 
reblotting) cytosolic and nuclear expressions are also shown to guarantee the successful cellular fractioning. (f) 
Representative photomicrographs of p65 NFκB immunofluorescence (red) in VSMC from SHR in control and 
after incubation with ET-1 (0.1 µM, 45 min, n = 7). Negative controls without primary or secondary antibody 
are also shown. Bar scale represents 50 µm. Statistical analysis by Student’s t-test; *P < 0.05 vs control and 
#P < 0.05 vs ET-1. n denotes number of experiments. Full-length blots are presented in Supplementary Fig. S3.
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that pioglitazone treatment reduced ETA and increased ETB transcription in aortic and mesenteric segments 
(Fig. 7a,b). These changes had functional consequences. Thus, in pioglitazone-treated rats, ET-1 reduced phenyle-
phrine contraction, effect prevented by the ETB antagonist BQ788 but not by the ETA antagonist BQ123 (Fig. 7c).
In pioglitazone-treated SHR, L-NAME leftward shifted phenylephrine response in control arteries (Fig. 7d). 
Notably, the effect of L-NAME was greater in arteries incubated with ET-1 (Fig. 7d), suggesting increased NO 
availability. Previously we have shown that ET-1 decreased the NO levels; after pioglitazone incubation, the NO 
levels were increased in ET-1-treated arteries; this increased in NO levels was prevented by BQ788 (Fig. 7e). 
Additionally, pioglitazone incubation improved the reduction on ACh-induced NO levels observed after ET-1 
(NO levels relative to control: ET-1, 76.3 ± 3.2%; ET-1+Pio, 97.0 ± 8.3%, n = 5, P < 0.05). On the other hand, 
the NADPH oxidase activity observed in ET-1-treated arteries was reduced by pioglitazone (Fig. 7f). Altogether, 
these results suggest that after pioglitazone treatment, ET-1/ETB pathway increases NO bioavailability reducing 
phenylephrine response; the antioxidant properties of pioglitazone likely contribute to this effect.
Figure 6. Contribution of AP-1 to the ET-1-induced oxidative stress and COX-2 expression in VSMC from 
hypertensive rats. Effect of SP600125 (SP, 20 µM) on NOX-1 mRNA levels (a), NADPH oxidase activity (b) 
and COX-2 protein expression (c) and mRNA levels (d) induced by ET-1 (0.1 µM, 1 h). *P < 0.05 vs control 
(Ctrl) and #P < 0.05 vs ET-1 by Student's t-test. (e) Time-course of ET-1 (0.1 µM)-induced p-JNK1/2 protein 
expression in VSMC from SHR; *P < 0.05 vs control (0´) by one-way ANOVA. A representative blot is shown 
in the upper panel; lower panel shows reblotting of upper panel with JNK2 antibody. (f) Effect of ET-1 (0.1 µM, 
1 h) on c-jun mRNA levels. Statistical analysis by Student's t-test. n denotes number of experiments. Full-length 
blots are presented in Supplementary Fig. S4.
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Figure 7. Effect of pioglitazone treatment of hypertensive rats on the vascular ET-1 receptors expression and 
ET-1 effect on phenylephrine contraction in MRA. Role of nitric oxide. ETA and ETB mRNA levels in aortic (a) 
and mesenteric (b) segments from SHR untreated and treated with pioglitazone (Pio, 2.5 mg/Kg·day, 28 days); 
*P < 0.05 by Student's t test. (c) Effect of ET-1 (1 nM, 90 min) and ET-1 plus BQ123 (1 µM) or BQ788 (1 µM) on 
the concentration-response curve to phenylephrine (Phe) in endothelium-intact segments from pioglitazone 
(Pio)-treated SHR; *P < 0.05 vs control; #P < 0.05 vs ET-1 by two-way ANOVA with repeated measures followed 
by Sidak or Tukey post hoc test. (d) Effect of 0.1 mM L-NAME on the response to Phe in control and ET-1-
incubated segments from SHR treated with pioglitazone; *P < 0.05 by two-way ANOVA with repeated measures 
followed by Sidak post hoc test. Differences of the AUC (dAUC) to Phe in the presence and the absence of 
L-NAME are also shown; *P < 0.05 by Student's t test. (e) Quantification of nitric oxide (NO) levels in vascular 
segments from SHR incubated with ET-1 (0.1 µM, 1 h) in the absence or the presence of Pio (10 µM, 18 h) and 
BQ788 (1 µM); *P < 0.05 vs ET-1 and #P < 0.05 vs ET-1+Pio by Student's t-test. (f) Quantification of NADPH 
oxidase activity in vascular segments from SHR incubated with ET-1 (0.1 µM, 1 h) in the absence or the presence 
of Pio (10 µM, 18 h); statistical analysis by Student's t test. n denotes number of experiments.
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Pioglitazone downregulates ET-1-induced COX-2 expression by interference with NFκB and 
AP-1 activation and reduction of ROS production in VSMC from SHR. In VSMCs from SHR, pio-
glitazone prevented ET-1-induced increase of NOX-1 protein and mRNA levels, NOX-4 mRNA levels, NADPH 
oxidase activity and superoxide anion production (Fig. 8a–e). In addition, pioglitazone reduced ET-1-induced 
COX-2 mRNA and protein levels (Fig. 8f,g) as well as the mRNA levels of the PGI2 synthase (relative expression: 
0.71 ± 0.06, n = 4, P < 0.05).
Glitazones interfere with NFκB and AP-1 activation by transrepression mechanisms5,36. Accordingly, piogl-
itazone diminished p65 nuclear expression (Fig. 9a,b; representative blot in Fig. 5e), JNK1/2 phosphorylation 
(Fig. 9c) and c-jun mRNA levels induced by ET-1 (Fig. 9d) in VSMCs from SHR. These results suggest that piogl-
itazone, by interfering with AP-1 and NFκB, might reduce ROS production and COX-2 expression.
Figure 8. Effect of pioglitazone on the role of oxidative stress to the ET-1-induced COX-2 expression in VSMC 
from hypertensive rats. Effect of pioglitazone (Pio, 10 µM, 18 h) on ET-1 (0.1 µM, 1 h)-induced NOX-1 protein 
expression (a) and mRNA levels (b), NOX-4 mRNA levels (c), NADPH oxidase activity (d), superoxide anion 
(O2−) production (e), and COX-2 protein expression (f) and mRNA levels (g) in vascular smooth muscle 
cells from SHR. Statistical analysis by Student's t-test. n denotes number of experiments. Full-length blots are 
presented in Supplementary Figs S2 and S5.
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Discussion
In the present study, we found that ET-1, through ETA, increased phenylephrine response in SHR by mecha-
nisms involving production of vasoconstrictor prostanoids from COX-2 and reduction of NO bioavailability, 
probably because of increased oxidative stress. Pioglitazone treatment of hypertensive animals decreased ETA 
and increased ETB expression. In these conditions, ET-1 acting on ETB, increased NO production and reduced 
phenylephrine-induced contraction. The antioxidant effect of pioglitazone likely contributed to decrease the 
COX-2 expression and to increase the NO bioavailability.
ET-1 levels are increased in some hypertension models5,37 and this peptide plays a role in 
hypertension-associated vascular damage38,39. ET-1 regulates vascular tone not only by inducing vasoconstric-
tion but also by modulating the response to other vasoactive agents; in addition, the proinflammatory proper-
ties of ET-1 seem to contribute to its hypertensinogenic effect21,22,40. Here we found greater ETA expression in 
vessels from SHR than WKY that likely explains the effect of a subthreshold concentration of ET-1 on elevating 
phenylephrine-induced responses only in SHR. This is in agreement with previous studies showing increased 
ETA levels in vessels from hypertensive animals41 and the involvement of this receptor in the vascular effects of 
ET-140,42,43; however, the contribution of ETB from VSMC to the vasomotor ET-1 effects in hypertension has also 
been reported44. In this study we did not find alterations in ETB expression or functional effects in hypertension.
L-NAME and endothelium removal increased the phenylephrine contraction in MRA from SHR, being this 
effect reduced after ET-1 incubation, suggesting that after ET-1, the NO contribution to phenylephrine-induced 
response is reduced; additionally, ET-1 reduced the basal NO levels, suggesting that, although induces eNOS 
Figure 9. Effect of pioglitazone on the role of NFκB and AP-1 to the ET-1-induced COX-2 expression in VSMC 
from hypertensive rats. (a) Effect of pioglitazone (Pio, 10 µM, 18 h) on ET-1 (0.1 µM, 45 min)-induced nuclear 
p65 NFκB protein expression in vascular smooth muscle cells (VSMC) from SHR; the representative blot of 
the cytosolic (Cy) and nuclear (Nu) expression is shown in Fig. 5E. (b) Representative photomicrographs of 
p65 NFκB immunofluorescence (red) in VSMC from SHR after incubation with ET-1 (0.1 µM, 45 min) in the 
absence and in the presence of pioglitazone. Bar scale represents 50 µm. Effect of pioglitazone on (c) p-JNK1/2 
protein expression (a representative blot is shown in the upper pane; lower panel shows reblotting of upper 
panel with JNK2 antibody) and (d) c-jun mRNA levels induced by ET-1 (0.1 µM, 15 min for p-JNK2 and 1 h for 
c-jun). Statistical analysis by Student's t-test. n denotes number of experiments. Full-length blots are presented 
in Supplementary Fig. S6.
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transcription, ET-1 reduces the NO bioavailability, thus contributing, at least partially, to the increased phenyle-
phrine contraction. In agreement to our results, after NO inhibition, ET-1 failed to further increase the con-
traction to electrical stimulation and 5-HT, as compared with that obtained in the absence of this peptide22,42. 
Accordingly with that found by other authors24–26, after incubation with ET-1 we found increased NADPH 
oxidase activity; along with this, the NOX inhibitor ML-171 reduced the contraction to phenylephrine in seg-
ments from ET-1-treated arteries. All these results suggest that the mechanism responsible for the increased 
phenylephrine-induced contraction elicited by ET-1 would be the production of ROS from NADPH oxidase 
reducing NO bioavailability. These would also explain the impairment of ACh-induced relaxation observed after 
ET-1 incubation. Additional mechanisms include activation of TP receptors by PGI2, as shown by the inhibitory 
effect of the PGI2 synthase inhibitor tranylcypromine in phenylephrine-induced contraction in ET-1-incubated 
segments. Although PGI2 is generally associated with vasodilator and antiagregant properties, in conditions such 
as hypertension or aging PGI2 binds TP receptors acting as a vasoconstrictor10,33. In addition, this COX-2-derived 
PGI2 is likely produced in VSMC since both NS398 and SQ29,548 reduced the effect of ET-1 on phenylephrine 
contraction also in endothelium denuded arteries. In agreement, ET-1 induced COX-2 and PGI2 synthase expres-
sion in VSMC from SHR. The enhanced COX-2 expression was dependent on oxidative stress because the anti-
oxidant apocynin decreased ET-1-induced COX-2 expression and ET-1 increased NOX-1, NOX-4 and NADPH 
oxidase activity in SHR VSMC. Other authors have described that ET-1 increases ROS production24–27 as well as 
the involvement of oxidative stress in the COX-2 expression induced by several stimuli in different cell types45.
The transcription factor NFκB is a downstream element of ET-1 signalling and its involvement in 
ET-1-induced COX-2 expression has been described in VSMC from SHR-SP3. In order to analyze the contribu-
tion of NFκB pathway, we used lactacystin, a natural nonpeptidic proteasome inhibitor that prevents degradation 
of the inhibitory proteins IκBs of the NFκB complex46. Lactacystin reduced ET-1-induced NOX-1 expression, 
NADPH oxidase activity and COX-2 expression in SHR VSMC, supporting the role of NFκB on ET-1/ROS/
COX-2 pathway. In agreement, ET-1 increased the nuclear translocation of the p65 NFκB subunit. Moreover, 
AP-1 seems to play a role in ET-1-induced ROS/COX-2 expression because ET-1 increased JNK1/2 phosphoryla-
tion and c-jun mRNA levels in cells from SHR and SP600125 reduced ET-1-induced oxidative stress and COX-2 
expression. In agreement, AP-1 dependent modulation of COX-2 was described in endothelial cells from brain 
mouse47, although other authors also showed COX-2 modulation by other kinases in response to ET-1 in micro-
vascular VSMC48; therefore, we cannot exclude the contribution of other signalling pathways in the ET-1 effect 
observed in our conditions.
PPARγ agonists have cardioprotective effects associated, among others, with improvement of vascular inflam-
mation7. Additionally, we and others have described that pioglitazone reduces ET-1 production, which might 
also contribute to its cardioprotective properties5,31,32,49. Furthermore, PPARγ regulates ET-1 activated processes 
such as vasoconstriction50 and cardiac hypertrophy51,52 and a recent report suggests that specific VSMC PPARγ 
counteracts ET-1-induced vascular damage6. Among the mechanisms responsible for these effects, earlier studies 
demonstrated that rosiglitazone reduces the contraction to ET-1 by reducing ETA and increasing ETB expres-
sion53,54, probably due to the fact that ETB gene is a direct target of the transcription factor PPARγ53. In agreement, 
we found lower levels of ETA and higher levels of ETB in vessels from pioglitazone-treated SHR that explains the 
ET-1/ETB-dependent reduction of phenylephrine contraction in these animals. Mechanistically, this effect was 
due to enhanced NO production as demonstrated by the greater effect of L-NAME on phenylephrine contraction 
and by the augmented ETB-dependent NO release in vessels from pioglitazone-treated SHR.
It has been described that PPARγ agonists reduce oxidative stress4,5,55,56. Here we found that pioglitazone 
treatment reduced the ET-1-induced oxidative stress in SHR vessels and VSMCs; then, we can conclude that the 
increased NO availability observed after pioglitazone treatment likely results from its antioxidant effects. This 
might also explain the reduction of ET-1-induced COX-2 expression observed in VSMCs from SHR, which is 
highly dependent on ROS, as demonstrated in this study. This is consistent with the reduction of COX-2 expres-
sion induced by several proinflammatory stimuli after PPARγ activation3–5. What is more, pioglitazone also 
reduced ET-1-induced PGIS levels. Furthermore, pioglitazone attenuated NFκB and AP-1 activation induced 
by ET-1. In agreement, SMC PPARγ reduces proinflammatory gene expression by inhibition of NFκB activity by 
promoting p65 nuclear export57 but to our knowledge, this is the first time that interference of pioglitazone with 
ET-1-induced AP-1 activation is described.
conclusion
Our results suggest that reduction of NO bioavailability and increased COX-2-derived PGI2 production, both 
mediated by oxidative stress, contribute to the hypercontractility to phenylephrine induced by ET-1 acting on ETA 
in vessels from hypertensive animals (Fig. 10). Treatment with pioglitazone along with reducing the ET-1 levels 
previously described5, also decreases ETA levels while increases those of ETB,; in these conditions, ET-1 through 
ETB increases the NO production. Additionally, pioglitazone reduces the ET-1-induced oxidative stress, contrib-
uting to increase NO bioavailability and to decrease COX-2 expression. All these mechanisms are responsible 
for the reduction of phenylephrine contraction induced by ET-1 after pioglitazone treatment (Fig. 10). These 
effects of glitazones on the ET-1 pathway would contribute to improve the cardiovascular alterations observed 
in hypertension and in other pathological diseases such as diabetes or cardiac hypertrophy32,49,55,58. Although 
ET-1 receptor antagonists have been demonstrated to be useful in the treatment of hypertension, they have not 
been approved yet in the clinic due to their side effects59. Because of the ability of pioglitazone to interfere with 
ET-1 system as well as to increase peripheral insulin sensitivity, this compound might be a promising thera-
peutic option in patients with resistant hypertension and in those with hypertension concomitant with insulin 
resistance.
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Material and Methods
Animals. All experimental procedures were approved by the Ethical Committee of Research of the 
Universidad Autónoma de Madrid and Dirección General de Medio Ambiente, Comunidad de Madrid, Spain 
(PROEX 345/14). Animal care and experimental procedures conformed to the current Spanish laws (RD 53/2013) 
and are also conformed to the Directive 2010/63/EU of the European Parliament for animal experiments. The 
studies also comply with the ARRIVE guidelines for reporting experiments involving animals. A total of 15 male 
WKY (355.7 ± 13.3 g) and 60 SHR (359.4 ± 8.2 g) rats five-six month-old were used.
Animals were obtained from colonies maintained at the Animal Quarters of the Facultad de Medicina of 
the Universidad Autónoma de Madrid. During treatment, rats were housed with constant room temperature, 
humidity and light cycle (12-h light/dark) and they had free access to tap water and were fed with standard rat 
chow ad libitum. The SHR rats were divided into two groups: control (received vehicle) and rats treated with the 
PPARγ agonist pioglitazone (2.5 mg/Kg·day, for 28 days suspended in 0.5% methylcellulose and administered in 
drinking water); this dose has been reported to achieve a concentration equivalent to that reported in humans 
who were administered a 15 mg dose of pioglitazone60. Previously we have reported that this treatment did not 
modify either blood pressure or body weight10. At the end of the treatment, rats were killed by decapitation and 
the mesenteric arcade was removed and placed in Krebs Henseleit solution (KHS) of the following composi-
tion (in mM): NaCl 115.0; KCl 4.7; CaCl2 2.5; KH2PO4 1.2; MgSO4.7H2O 1.2; NaHCO3 25.0; glucose 11.1 and 
Na2EDTA 0.01, maintained at 4 °C and continuously gassed with 95% O2 and 5% CO2. Segments of third-order 
branches of the mesenteric artery (MRA) were dissected free of fat and connective tissue and used for vascular 
function studies. Aortas were used to isolate VSMC as well as to analyse the vascular mRNA and NO levels and 
the NADPH oxidase activity.
Reactivity experiments. Ring segments, 2 mm in length, were mounted in a small vessel dual chamber 
myograph for isometric tension measurement10. Segments contractility was tested by an initial exposure to a 
high K+ solution (120 mM K+-KHS, which was identical to KHS except that NaCl was replaced by KCl on an 
Figure 10. Scheme illustrating the proposed mechanism by which ET-1 increases phenylephrine-induced 
contraction in hypertension and the effect of PPARγ activation. In segments from hypertensive rats, ET-1, 
acting on ETA receptors, increases NOX-1 mRNA levels and NADPH oxidase activity through NFκB and AP-1 
activation in vascular smooth muscle cells. This enhanced ROS production induces COX-2 expression that 
together with augmented PGIS expression lead to PGI2-dependent activation of TP receptors that increases the 
contraction induced by phenylephrine; in addition, the increased oxidative stress reduces NO bioavailability, 
which also contributes to ET-induced effects on phenylephrine response. After pioglitazone treatment, there 
is a reduction of smooth muscle ETA levels and an increase of endothelial ETB. In these conditions, ET-1, 
acting on ETB, increases NO production; the reduction of oxidative stress due to attenuated NFκB and AP-1 
activities induced by pioglitazone contributes to decrease COX-2 expression and to increase NO bioavailability; 
these mechanisms play a role in the reduction induced by ET-1 of the phenylephrine response observed after 
pioglitazone treatment.
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equimolar basis). The response to K+-KHS was similar (P >  0.05) in arteries from the three groups (in mN/
mm: WKY: 3.04 ± 0.07, n = 15; SHR: 3.12 ± 0.09, n = 24; SHR pioglitazone: 3.23 ± 0.13, n = 13). The presence 
of endothelium was determined by the ability of 10 μM acetylcholine (ACh) to relax arteries precontracted with 
phenylephrine at a concentration that produce approximately 50% of the contraction induced by K+-KHS in each 
case. Thereafter, the vascular segments were incubated with 1 nM ET-1 90 min prior to perform a cumulative 
concentration-response curve to phenylephrine (0.1–30 µM). The effects of indomethacin, NS398, SQ29,548, 
SC19220, furegrelate, tranylcypromine, L-NAME and ML-171 (2-acetylphenothiazine) were analysed by their 
addition 30 min before the phenylephrine concentration-response curve. The effects of BQ123 and BQ788 on the 
ET-1-induced effect were analysed by their addition 30 min before ET-1. In some experiments, endothelium was 
mechanically removed and the effect of ET-1 on the phenylephrine response was analysed in the absence and the 
presence of NS398 and SQ29,548. Endothelium removal was assessed by the inability of 10 μM ACh to produce 
vasodilation. In order to analyze the effect of ET-1 on ACh-induced relaxation, vessels were incubated for 90 min 
prior to phenylephrine contraction and then a cumulative concentration-response curve to ACh was performed; 
in some segments, L-NAME was added 30 min before phenylephrine.
Vasoconstrictor responses were expressed as a percentage of the tone generated by K+-KHS.
Cell cultures. Primary cultures of VSMC were obtained from thoracic aortas of 5-month-old SHRs. For this, 
aortas were aseptically removed, cleaned of fat tissue and blood cells, and placed in DMEM (Invitrogen Life 
Technologies, Carlsbad, CA, USA) at 4 °C containing 2 mg/ml collagenase type 2 (Invitrogen Life Technologies), 
0.1% BSA, 200 U/ml penicillin and 200 μg/ml streptomycin (Sigma Chemical Co., St. Louis, MO, USA). After 
carefully removal of adventitia, VSMC were obtained by the explant method5. Cells from passages 3–8, made qui-
escent by incubation in DMEM containing 0.2% FBS for 24 h, were used. Cells were identified as VSMCs by the 
typical spindle shape, by the typical “hills and valleys” distribution, and by positive immunocytochemical staining 
with specific monoclonal anti-α-actin antibody (Sigma Chemical catalogue number A2547, lot 084M4795V). 
Cells were stimulated with 0.1 μM ET-1 (for the times indicated in each case) with or without pretreatment for 
18 h with pioglitazone or for 1 h with apocynin, catalase, SP600125 or lactacystin.
Protein expression determination by Western blot. The protein expression was determined by west-
ern blot in total extracts (20–25 µg) or nuclear and cytosolic extracts (15 µg) from VSMC. Proteins were sepa-
rated by 10% SDS-PAGE and transferred to polyvinyl difluoride membranes that were incubated with rabbit 
polyclonal antibodies for COX-2 (1:250; Cayman Chemical, Ann Arbor, MI, USA, catalogue number 160106, 
lot 0439169–1), NOX-1 (1:1,000; Abcam, Cambridge, UK, catalogue number ab131088, lot GR3244226-4), p65 
(1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA, USA, catalogue number sc-372, lot BO513) or p-JNK1/2 
(1:1,000, Cell Signaling Technology, Danvers, MA, USA, catalogue number #9251, lot 24). After being washed, 
membranes were incubated with anti-rabbit (1:5,000, Bio-Rad, Laboratories, Hercules, CA, USA, catalogue num-
ber 70-6515, lot L005679A) or anti-mouse (1:5,000, StressGen, Ann Arbor, MI, USA, catalogue number SAB-100, 
lot 02020904) IgG antibody conjugated to horseradish peroxidase. The immunocomplexes were detected using 
an enhanced horseradish peroxidase-luminol chemiluminiscence system (ECL Plus, Amersham Biosciences, GE 
Healthcare, Little Chalfont, UK) and subjected to autoradiography (Minolta Film, Konica Minolta, Wayne, NJ, 
USA) or with the ChemiDocTMMP Imaging System (Bio-Rad Laboratories). Signals on the immunoblot were 
quantified using the Typhoon 9210 quantification software (Amersham Biosciences) or the Image lab Software 
version 6.0 (Bio-Rad Laboratories). The same membrane was used to determine the expression of α-actin (mouse, 
1:250,000, Sigma Chemical Co.) and JNK2 (rabbit, 1:1,000, Cell Signalling Technology, catalogue number #9258, 
lot 11) in total extract or TATA-binding protein (TBP, rabbit, 1:1,000, Santa Cruz Biotechnology, catalogue 
number sc-204, lot LO214) and GAPDH (mouse, 1:4,000, Calbiochem, Temecula, CA, USA, catalogue number 
CB1001, lot 2868983) in nuclear and cytosolic extracts, respectively. Data of protein expression were expressed 
as the ratio between signals on the immunoblot corresponding to the protein studied and that of α-actin, JNK2 
or TBP. To compare the results for protein expression, we assigned a value of 1 to the control or ET-1 situation.
Immunofluorescence. Proteins were also analysed by immunofluorescence, as previously described5. For 
this, VSMCs were seeded in a 24-well culture plate with coverglasses in the bottom surface. After 60% conflu-
ence was reached, cultures were starved in DMEM with 0.1% FBS for 24 h and then stimulated with 0.1 μM ET-1 
(45 min) after treatment or not with pioglitazone (10 μM, 18 h). At the end of the treatment, cells were washed 
and fixed in 4% paraformaldehyde diluted in PBS and maintained in PBS containing 0.2% BSA. Then, cells were 
incubated overnight at 4 °C with rabbit polyclonal antibody anti-p65 (1:200 dilution). After being washed, red 
FITC-conjugated goat anti-rabbit antibody (Molecular Probes, Life Technologies, Paisley, UK) was added to 
the cells at 1:2,000 dilution in the dark. As negative controls we performed the protocol in cells without either 
primary or secondary antibodies; no staining was observed in both conditions (Fig. 5f). After washing, cells 
were incubated for 15 min with 4′,6-di-amidino-2-phenylindole (1:10,000, Invitrogen Life Technologies) to stain 
nuclei, and ProLong Gold antifade mounting reagent (Invitrogen Life Technologies) was added to the microscope 
slides. Then, fixed and treated cells were placed and sealed in the slides and allowed to completely dry in the dark 
until the next day. Immunofluorescence-stained cells were observed under a laser scanning confocal microscope 
(Nikon, C1plus, Nikon Instruments, Melville, NY, USA) and analysed using ImageJ software (http://rsb.info.nih.
gov/ij). The fluorescence intensity of cells was measured at four preset areas per sample, and at least three inde-
pendent experiments were performed.
mRNA levels determined by qRT-PCR assay. ETA, ETB, PPARγ and eNOS mRNA levels were deter-
mined in mesenteric and/or aortic segments and COX-2, prostacyclin synthase (PGIS), NOX-1, NOX-4 and 
c-jun mRNA levels in VSMC. Total RNA was obtained by using TRIzol (Invitrogen Life Technologies). A total 
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of 1 μg of DNAse I treated RNA was reverse-transcribed into cDNA using the High Capacity cDNA Archive 
Kit (Applied Biosystems, Foster City, CA, USA) in a 50 μl reaction. PCR was performed in duplicate for each 
sample using 0.5 μl of cDNA as template, 1x TaqMan Universal PCR Master Mix (Applied Biosystems) and 20x 
of Taqman Gene Expression Assays (Applied Biosystems, COX-2: Rn00568225_m1; NOX-1: Rn00586652_m1; 
c-jun: Rn00440945_m1) or specific primers (Sigma-Aldrich, ETA Fw: GCCATTGAAATTGTCTCCATCTGG, 
Rv: GAACTTGGTCGTGGCGTTGA; ETB Fw: GATACGACAACTTCCGCTCCA, Rv: GTCCACGATGAGG 
ACAATGAG; PPARγ Fw: TCGCTGATGCACTGCCTATG, Rv; GGAGTGGTCATCCATCACAG; eNOS Fw: GAGA 
GTGAGCTGGTGTTTGG, Rv: GGTGAACATTTCCTGTGCTGT; NOX-4 Fw: GCCTCCATCAAGCCAAGA, 
Rv: CCAGTCATCCAGTAGAGTG; PGIS Fw: CCATCAACAGCATCAAACAGTTT, Rv: CAAAGCCATATC 
TGCTAAGGTCAA), and Fast Start Universal SYBR Green Master (Rox) in a 20 μl reaction. For quantification, 
quantitative RT-PCR was carried out in an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, 
from the CAT of Universidad Rey Juan Carlos) using the following conditions: 2 min 50 °C, 10 min 95 °C and 40 
cycles: 15 s 95 °C, 1 min 60 °C. As a normalizing internal control we amplified β2 microglobulin (Rn00560865_
m1) and cyclophilin D (Rn01458750_g1). To calculate the relative index of gene expression, we used the 2−ΔΔCt 
method; for comparisons, we used WKY or untreated SHR as a control situation in vascular segments and control 
or ET-1-treated cultures in VSMC.
In situ detection of vascular O2·− production. The oxidative fluorescent dye dihydroethidium (DHE) 
was used to evaluate in situ O2∙− production in VSMCs, as previously described5. Hydroethidine freely permeates 
cells and is oxidized in the presence of O2∙− to ethidium bromide, which is trapped by intercalation with DNA. 
Ethidium bromide is excited at 546 nm and has an emission spectrum at 600–700 nm. VSMCs were plated onto 
glass coverslips inserted into six-well plates and cultured as described above. Subconfluent cells were stimulated 
with ET-1 (0.1 μM) for 1 h in the absence and presence of pioglitazone or apocynin that were respectively added 
18 h or 1 h before ET-1. Afterwards, cells were loaded with DHE (10 µM) in serum-free DMEM with 0.1% BSA 
for 30 min at 37 °C. Nonstimulated VSMCs were imaged daily in parallel using the same image settings. Images 
were captured with a fluorescent laser scanning confocal microscope (Leica TCS SP2). The fluorescence intensity 
values of 10–20 nuclei per experiment were measured using the Metamorph Image Analysis Software (Molecular 
Devices, Downingtown, PA, USA).
Lucigenin assay. A lucigenin-enhanced chemiluminescence assay was used to determine NADPH oxidase 
activity in aortic segments and VSMCs. Arterial segments from the same animal and VSMCs from the same 
batch were incubated or not with ET-1, previously treated or not with pioglitazone, lactacystin or SP600125. 
Aortic segments or VSMCs were homogenized in lysis buffer (in mM: 50 KH2PO4, 1 EGTA and 150 sucrose, 
pH 7.4) on ice to avoid degradation. Protein concentration was determined by using the Bradford reactive and 
50 μl of the homogenate (containing 50 µg protein in VSMC and 75–100 µg protein in aortic segments) were 
transferred to a 96 well plate together with 175 μl of assay phosphate buffer and lucigenin (5 µM); the assay was 
performed by duplicate. Basal luminescence was measured every 1.8 seconds during 3 minutes in a plate lumi-
nometer (Auto-Lumat LB 953, Berthold Technologies, Bad Wildbad, Germany). The reaction was started by the 
addition of NADPH (0.1 mM) and luminescence was measure every 1.8 seconds during 3 minutes. The buffer 
blank was subtracted from each reading. Activity was expressed as relative light units per μg of protein. Variations 
of luminescence were calculated as the amount relative to control or ET-1-treated arterial segments from the same 
animal or VSMCs from the same batch.
NO release. NO levels were analyzed in aortic segments from SHR rats with the fluorescent probe 
4,5-diaminofluorescein (DAF-2), as described29; each day, one segment was used as control and others from the 
same animal were incubated with ET-1 previously treated or not with pioglitazone with or without BQ788. Then, 
vascular segments were stabilized in a Krebs-HEPES buffer (in mM: 119 NaCl; 20 HEPES; 1.2 CaCl2; 4.6 KCl; 1 
MgSO4; 0.4 KH2PO4; 5 NaHCO3; 5.5 glucose; 0.15 Na2HPO4, pH 7.4) at 37 °C for 30 min. Subsequently, segments 
were incubated with DAF-2 (20 µM in Krebs-HEPES) at 37 °C for 45 min. Segments were made permeable with 
0.05% triton for 3 min, and the levels of NO were measured using a fluorometer (FLUOstar OPTIMA, BGM 
Labtech, Ortenberg, Germany). To analyze the effect of ET-1 on ACh-induced NO release, some segments were 
incubated with phenylephrine (1 µM, 5 min) and ACh (10 µM, 10 min). Thereafter, the medium was collected to 
measure agonist-induced NO release. The induced NO release was calculated by subtracting basal NO release 
from that evoked by ACh. At the end of the experiments, aortic segments were weighted to correct the NO 
release. For negative controls, one segment was incubated as above indicated with 0.1 mM L-NAME. A tube with-
out aortic segment was included as blank. The amount of NO released was expressed as arbitrary units per mg of 
dry tissue. Variations of NO release were calculated as the amount relative to control or ET-1-treated segments 
from the same animal.
Data analysis. All values are expressed as mean ± standard error (S.E.M.); n denotes the number of animals 
or the number of different cultures (each one obtained from three different animals) used in each experiment. 
In vascular reactivity experiments, the maximum response (Emax values) and the negative logarithm of concen-
trations of phenylephrine producing 50% of maximum response (pD2 values), were calculated by a non-linear 
regression analysis of each individual concentration-response curve using a computer program (GraphPad Prism 
Software, San Diego, CA, USA). To compare the effects of L-NAME or endothelium removal on the response 
to phenylephrine in segments from different groups, results are also expressed as differences of area under the 
concentration-response curve (dAUC) in control and experimental situations. AUCs were calculated from 
the individual concentration-response curve plots using the GraphPad Prism Software; the differences were 
expressed as a percentage of the AUC of the corresponding control situation. In the cell culture experiments, 
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since the different wells of one plate have been seeded with the same batch of cells, we consider the other wells as 
the same subject; therefore, data are expressed as a n-fold increase relative to control in each plate, value of which 
was 1. Results were analysed by using Student's t-test or two-way ANOVA with or without repeated measures 
followed by Tukey or Sidak test for multiple comparisons by using the GraphPad Prism Software version 7.04. P 
≤0.05 was considered as significant differences.
Materials. Phenylephrine, ACh, SC19220, furegrelate, tranylcypromine, L-NAME, ML-171, catalase, lac-
tacystin, SP600125, indomethacin, BQ123 and BQ788 were obtained from Sigma Chemical, Co. NS398 was 
obtained from Calbiochem-Novabiochem GmbH (Bad Soden, Germany), apocynin from Fluka-Sigma Chemical 
(Seelze, Germany) and SQ29,548 from Cayman Chemical. Pioglitazone was generously supplied by Takeda-Lilly, 
Madrid, Spain.
Data availability
All data generated or analyzed during this study are included in this article (and its Supplementary Information file).
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